- Home
- ANIP
as 07-30-2025 10:30am EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as ANI Pharmaceuticals Inc. ANIP prepares to release earnings report on 05 Aug 2025.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $80.56 | AVG Volume (30 days): | 289.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $52.50 - $77.00 | Next Earning Date: | 08-05-2025 |
| Revenue: | $674,068,000 | Revenue Growth: | 30.27% |
| Revenue Growth (this year): | 30.84% | Revenue Growth (next year): | 7.39% |
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Jun 13 '25 | Sell | $61.37 | 400 | $24,548.00 | 79,345 | |
| Gutwerg Ori | ANIP | SVP, GENERICS | May 15 '25 | Sell | $60.07 | 881 | $52,921.67 | 89,897 | |
| Mutz Christopher | ANIP | HEAD OF RARE DISEASE | May 14 '25 | Sell | $60.45 | 4,000 | $241,800.00 | 107,317 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | May 13 '25 | Sell | $62.20 | 400 | $24,880.00 | 79,345 | |
| Shanmugam Muthusamy | ANIP | HEAD OF R&D, COO-NOVITIUM OPS | May 9 '25 | Sell | $76.83 | 700 | $53,781.00 | 631,920 |
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
StockStory
a month ago
The Top 5 Analyst Questions From ANI Pharmaceuticals’s Q1 Earnings Call
Argus Research
a month ago
ANIP: Raising target price to $70.00
StockStory
a month ago
ANI Pharmaceuticals (NASDAQ:ANIP) Q1 Earnings: Leading The Generic Pharmaceuticals Pack
StockStory
a month ago
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
GlobeNewswire
2 months ago
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
StockStory
2 months ago
3 Healthcare Stocks with Mounting Challenges
StockStory
2 months ago
3 Cash-Producing Stocks in the Doghouse
StockStory
2 months ago
ANIP Q1 CY2025 Earnings Call: Generics, Rare Disease Drive Growth; Retina Headwinds Noted
Compare ANIP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.